Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
1. A method of treating asthma comprising administering to a human in need thereof a therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the asthma is selected from atopic asthma, allergic asthma, persistent asthma, mild asthma, moderate asthma, severe asthma and any combination thereof.
3. The method of claim 1 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
4. The method of claim 1 , further comprising measuring the level of eosinophils in the subject's peripheral blood, tissue, or a combination thereof.
5. The method of claim 4 , wherein the level of eosinophils is selected from the group consisting of at or above 100 cells per microliter in peripheral blood, at or above 150 cells per microliter in peripheral blood, at or above 200 cells per microliter in peripheral blood, and at or above 300 cells per microliter in peripheral blood.
6. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is from about 50 milligrams to about 1,500 milligrams per day.
7. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
8. The method of claim 1 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is administered in a solid unit dose selected from a tablet or capsule.
9. The method of claim 1 , wherein administering comprises administering a fraction of the daily dose two or more times per day.
10. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered as an initial dosing regimen followed by administration of a therapeutically effective amount of dexpramipexole or a pharmaceutically acceptable salt thereof as a maintenance dosing regimen.
11. The method of claim 10 , wherein the initial dosing regimen is administered for about 1 week to about 12 weeks.
12. The method of claim 10 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 50 milligrams to about 1,500 milligrams per day.
13. The method of claim 10 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 150 milligrams to about 300 milligrams per day.
14. The method of claim 1 , further comprising administration of an induction step.
15. The method of claim 14 , wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels selected from the group consisting of corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent and a combination thereof.
16. The method of claim 14 , wherein said administration of the induction step is from about 1 week to about 6 months.
17. The method of claim 1 , wherein therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered via a route of administration selected from the group consisting of orally, by inhalation, intranasally, via intravenous administration, topically, and any combination thereof.
18. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of one or more secondary agents.
19. The method of claim 18 , wherein the secondary agent is selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a phenolic antioxidant, an anti-proliferative drug, a tyrosine kinase inhibitor, an anti IL-5 monoclonal antibody, an IL5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an IL-4 monoclonal antibody, an IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a TNF-α inhibitor, a fusion protein, a chemotherapeutic agent, and a combination thereof.
20. The method of claim 1 , wherein the asthma is eosinophilic asthma.
21. The method of claim 20 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
22. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is from about 50 milligrams to about 1,500 milligrams per day.
23. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
24. The method of claim 22 , wherein administering comprises administering a fraction of the daily dose two or more times per day.
25. The method of claim 20 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is administered in a solid unit dose selected from a tablet or capsule.
26. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered as an initial dosing regimen followed by administration of a therapeutically effective amount of dexpramipexole or a pharmaceutically acceptable salt thereof as a maintenance dosing regimen.
27. The method of claim 26 , wherein the initial dosing regimen is administered for about 1 week to about 12 weeks.
28. The method of claim 26 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 50 milligrams to about 1,500 milligrams per day.
29. The method of claim 26 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 150 milligrams to about 300 milligrams per day.
30. The method of claim 20 , further comprising administration of an induction step.
31. The method of claim 30 , wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels selected from the group consisting of corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent and a combination thereof.
32. The method of claim 30 , wherein said administration of an induction step is from about 1 week to about 6 months.
33. The method of claim 20 , wherein therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is administered via a route of administration selected from the group consisting of orally, by inhalation, intranasally, via intravenous administration, topically, and any combination thereof.
34. The method of claim 20 , further comprising administering to the subject a therapeutically effective amount of one or more secondary agents.
35. The method of claim 34 , wherein the secondary agent is selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a phenolic antioxidant, an anti-proliferative drug, a tyrosine kinase inhibitor, an anti IL-5 monoclonal antibody, an IL5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an IL-4 monoclonal antibody, an IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a TNF-α inhibitor, a fusion protein, a chemotherapeutic agent, and a combination thereof.
36. The method of claim 10 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 300 milligrams to about 600 milligrams per day.
37. The method of claim 10 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 75 milligrams to about 150 milligrams per day.
38. The method of claim 26 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 300 milligrams to about 600 milligrams per day.
39. The method of claim 26 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 75 milligrams to about 150 milligrams per day.
40. The method of claim 18 , wherein the secondary agent is a corticosteroid.
41. The method of claim 34 , wherein the secondary agent is a corticosteroid.
42. The method of claim 18 , wherein the secondary agent is a monoclonal antibody selected from a group consisting of an anti IL-5 monoclonal antibody, an IL5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an IL-4 monoclonal antibody, an IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a monoclonal antibody directed against one or more pro-inflammatory cytokines, and a combination thereof.
43. The method of claim 34 , wherein the secondary agent is a monoclonal antibody selected from a group consisting of an anti IL-5 monoclonal antibody, an IL5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an IL-4 monoclonal antibody, an IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a monoclonal antibody directed against one or more pro-inflammatory cytokines, and a combination thereof.
44. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
45. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
46. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
47. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
48. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams twice per day.
49. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams twice per day.
50. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams twice per day.
51. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams twice per day.
52. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 37.5 milligrams twice per day.
53. The method of claim 20 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 37.5 milligrams twice per day.
54. The method of claim 20 , further comprising measuring the level of eosinophils in the subject's peripheral blood, tissue, or a combination thereof.
55. The method of claim 54 , wherein the level of eosinophils is selected from the group consisting of at or above 100 cells per microliter in peripheral blood, at or above 150 cells per microliter in peripheral blood, at or above 200 cells per microliter in peripheral blood, and at or above 300 cells per microliter in peripheral blood.